

## Drug and Therapeutics Committee – Minutes – Confirmed

<b>Date / Time</b>	Thursday 13 <sup>th</sup> August 2020 8:15am – 9:30am
<b>Venue</b>	Webex
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Mrs W Hornsby, Senior Pharmacy Technician
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics (until 9am) Mr K McCorry, Medicines Optimisation Pharmacist, NECS Dr B Ali, GP Hull CCG Ms J Morgan, Professional Secretary, Senior Principal Pharmacist – Formulary Dr H Klonin, Consultant Paediatrician Prof M Lind, Vice Chair, Professor of Oncology Dr O Ogunbambi, Consultant Rheumatologist Dr A Sampson, Consultant Infectious Diseases
-------------------	---

<b>Apologies</b>	Mr R Kapur, Vascular Surgeon, HUTH
------------------	------------------------------------

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2020.08.01	Apologies	As above					08.20
2020.08.02	Declarations of Interest	None this month					
2020.08.03	Minutes of the previous meeting	Accepted as a true record	Noted	No further action			8.20
2020.08.04	Action Tracker	<b>New Product Request</b> ML has written to interventional radiology requesting a protocol	Action complete	No further action	ML		8.20
		<b>Chairs Approval</b> Veliparib – ML discussed with relevant consultant and made clear that all requests of this nature must go through the D&T process and the pharmacy dept must be informed. .	Action complete	No further action	ML		8.20
		<b>Tracker</b> DC said the trust are working on a project over the next 3 to 4 months regarding lay members and thought it would be useful to raise this when the committee presents its annual report in October to OQC.	Action complete	No further action	DC		8.20
		<b>New Product Requests</b> AM has written to applicants and WH has update formulary	Action complete	No further action	AM/WH		8.20
		<b>New Product Requests</b> JM has requested protocol be written for the use of Fremanezumab and it is on the agenda for discussion	Action complete	No further action	JM		8.20
		<b>New Product Requests – Fremanezumab</b> POB has sent PAS price to KMc	Action complete	No further action	POB		8.20
		<b>New Product Requests</b> JM reported back on decision around migraine products	Action complete	No further	JM		8.20

		<p><b>NICE Guidance</b> TA626 Avatrombopag JM has discussed with Dr Corless</p> <p><b>NICE Guidance</b> HK fed back on NG29 IV fluid therapy in children and young people in hospital she has discussed with members of the paediatric team</p> <p><b>Correspondence Received</b> WH has added Esperoct (Turoctocog alfa pegol) to the formulary</p> <p><b>Issues to escalate to OQC</b> JM requested template for annual report in preparation for October 2020, but was told that report could be presented in any format D&amp;T committee saw fit.</p>	Action complete	action No further action	JM		8.20
			Action complete	No further action	HK		8.20
			Action complete	No further action	WH		8.20
			Action complete	No further action	JM		8.20
2020.08.05	<b>New Product Requests</b>	<p><b>Dupilumab – Moderate to Severe Atopic Eczema Children 6-12years EAMS – Dr Zaman</b> EAMS not yet launched but product already in use for adults and older children. POB pointed out that there is a risk that between the EAMS being published and the NHSE funding initiation there will be a gap where the trust may be requested to pay full price for treatment The Health Group needs to understand if this were to occur they would be liable to pick up the costs.</p> <p><b>Espranor - buprenorphine product used by CGL – line extension</b> Requested as line extension as RENEW are using this form and there is a disruption in treatment if HUTH cannot provide to inpatients.</p> <p><b>Glycopyrronium liquid – line extension (paediatrics) - Sialhorrhea</b> Licensed liquid now available. Paediatrics have requested initially for the treatment of 2 patients instead of using unlicensed preparation. Glycopyrronium is recommended in the following NICE guidance NG71 Parkinsons Disease</p>	Approved subject to EAMS publication				
			HG to be informed	POB to email Colin Vize	POB	9.20	
			Approved				
			Approved	Discuss at HERPC to confirm traffic light status	WH	9.20	

		<p>NG42 Motor Neurone Disease NG62 Cerebral Palsy JM has requested paediatric pharmacist prepare protocol referencing pharmacological and non-pharmacological treatments for this condition. The committee discussed who would be responsible for prescribing as dose needs complex titration at initiation, agreed to discuss at HERPC</p> <p><b>Alcohol 18% eye application – corneal debridement – Mr Goel</b> Currently options for debridement are laser treatment or surgical removal with a blunt scalpel. Trial information demonstrated 18% alcohol is not inferior to either of these methods and although the main adverse effect was more pain on day 1 overall the patient experience was improved due to decreased anxiety.</p> <p><b>Susoctocog Alfa (Obizur) – Aquired Haemophilia Poorly Responsive to Established Therapy – Dr Alsup</b> Requested as option for rare poorly responsive cases, NHSE Funded.</p>	<p>Approved</p> <p>Approved</p>	<p>AM to write to all applicants and WH to update formulary</p>	AM/WH	9.20	
2020.08.06	<b>NICE Guidance</b>	<ul style="list-style-type: none"> <li>• TA638 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer</li> <li>• TA639 Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer</li> <li>• NG167 COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders</li> <li>• NG179 COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services</li> <li>• NG 164 COVID-19 rapid guideline: haematopoietic stem cell transplantation</li> <li>• NG174 COVID-19 rapid guideline: children and young people who are immunocompromised</li> </ul>	<p>Already on formulary for other indications</p> <p>Noted, no reference to any specific medicines</p>	<p>JM to request ARIA forms</p> <p>No further action</p>	JM	9.20	
2020.08.07	<b>MHRA Drug Safety Update</b>	<p><b>Systemically administered VEGF pathway inhibitors:Risk of aneurysm and artery dissection</b> No specific recommendations, ML said all oncologists who use are very familiar with the vascular side effects the main one being hypertension.</p>	<p>JM to add to OQC annual report from D&amp;T</p>		JM	9.20	

		<b>Liposomal and Lipid complex formulations: Name change to reduce medication errors</b>					
			Noted				
2020.08.08	<b>Covid Guidelines</b>	Remdesivir prescription/guideline (update)  Clinical guidance for COVID19 (update to reflect dexamethasone guidance CMO26)	Documents were shared with committee and approved prior to meeting	No further action			8.20
2020.08.09	<b>Fremanezumab for Chronic Migraine Guideline</b>	Guideline from neurology department has already been approved by Neurology governance, requires greater than 30% reduction in migraines for continued use. CCG responsible for funding. BA asked who would perform 12 week review JM said it would be either a specialist nurse or consultant from the headache team. Professor Ahmed will be providing at NHS Spire clinics funded by CCG, and should be purchased using PAS scheme, use of Fremanezumab will potentially reduce amount of BOTOX used. KMc said both CCGs will need to approve	Discuss further at HERPC	WH to add to HERPC agenda	WH	9.20	
2020.08.10	<b>Minutes SMPC</b>	<b>May 2020</b> Main items for discussion were: Oxford vaccine trial and use of multidose vials Guidelines not always approved appropriately in fast moving environment CD ordering changed for some wards to avoid staff having to change multiple times in order to go to pharmacy	Noted				8.20
2020.08.11	<b>Minutes from HERPC</b>	<b>May 2020</b>	Noted				8.20
2020.08.12	<b>Regional Medicines Optimisation Committees</b>	None this month					8.20
2020.08.13	<b>Correspondence received</b>	None this month					8.20

2020.08.14	<b>Chairs approvals</b>	<b>Rituximab - Susacs syndrome - Dr J Harley</b> AM requested that Dr Harley report back on patients condition	JM to contact Dr Harley		JM	9.20	
2020.08.15	<b>Issues to escalate to OQC</b>	None this month			D		8.20
2020.08.16	<b>Any Other Business</b>	AM said that Dr Umerah had retired from the committee and took the opportunity to give grateful thanks for her contribution to the committee over the years.  BA asked if WH could arrange for meeting on WEBEX to be set up earlier as it was taking members who were not part of the trust longer to log on, WH agreed to do this.	Noted  WH to arrange for WEBEX to start earlier		WH	9.20	
	<b>Date and Time of Next Meeting</b>	<b>Date:</b> Thursday 10th September 2020 <b>Time:</b> 8.15-9.30am <b>Venue:</b> Webex					